SCHEMBL4184428

SCHEMBL4184428

NS(=O)(=O)CCc1ccccn1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.57
ALDH1A1 P00352 4/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
POLB P06746 1/20 0.51
HRH3 Q9Y5N1 1/20 0.47
TAAR1 Q96RJ0 1/20 0.46
ALOX15 P16050 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CYP1A2 P05177 1/20 0.44
PRMT1 Q99873 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063300 0.98 HRH1 (0.55) HRH1ALDH1A1NPC1RAB9ALMNA
Potassium SCHEMBL4063307 0.98 HRH1 (0.55) HRH1ALDH1A1NPC1RAB9ALMNA
SCHEMBL4249546 0.89 HRH1 (0.56) HRH1ALDH1A1NPC1RAB9ALMNA
SCHEMBL4131768 0.81 ALDH1A1 (0.53) HRH1ALDH1A1NPC1RAB9ALMNA
SCHEMBL1272589 0.81 LMNA (0.60) HRH1ALDH1A1NPC1RAB9ALMNA
SCHEMBL1272587 0.81 ALDH1A1 (0.53) HRH1ALDH1A1NPC1RAB9ALMNA
SCHEMBL497367 0.81 LMNA (0.60) HRH1ALDH1A1NPC1RAB9ALMNA
SCHEMBL51377 0.80 HRH1 (0.50) HRH1LMNATDP1KMT2AL3MBTL1
SCHEMBL29596510 0.80 HRH1 (0.50) HRH1LMNATDP1KMT2AL3MBTL1
Potassium Ion SCHEMBL9065490 0.79 ALDH1A1 (0.55) HRH1ALDH1A1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049494-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2009-04-22 EP claimed
WO-2008008310-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2008-01-17 WO claimed
EP-1735284-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES Pfizer Limited (GB) 2006-12-27 EP claimed
WO-2005090313-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES PFIZER LIMITED (GB) 2005-09-29 WO claimed
US-11807624-B2 Substituted pyrimidinones as agonists of the APJ receptor AMGEN INC. (US) 2023-11-07 US disclosed
US-11724997-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2023-08-15 US disclosed
US-11724997-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2023-08-15 US disclosed
US-20210246118-A1 SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2021-08-12 US disclosed
US-20210053936-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. 2021-02-25 US disclosed
CN-112055713-A Compounds and compositions for treating diseases associated with APJ receptor activity 安娜普尔纳生物股份有限公司 2020-12-08 CN disclosed
EP-2049494-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2009-04-22 EP disclosed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed
WO-2008008310-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2008-01-17 WO disclosed
EP-1735284-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES Pfizer Limited (GB) 2006-12-27 EP disclosed
WO-2005090313-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES PFIZER LIMITED (GB) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11724997-B2 Compounds and compositions for treating conditions associated with APJ receptor activity APLNR, AGTR1, AGTR2 HRH1 1942/4885ALDH1A1 2778/4885NPC1 2329/4885
US-20210053936-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 HRH1 1942/4885ALDH1A1 2778/4885NPC1 2329/4885
US-20210246118-A1 SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR APLNR, AGTR1, AGTR2 HRH1 1087/4885ALDH1A1 1619/4885NPC1 2682/4885
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 HRH1 757/4885ALDH1A1 2269/4885NPC1 1077/4885
US-11807624-B2 Substituted pyrimidinones as agonists of the APJ receptor APLNR, AGTR1, AGTR2 HRH1 1087/4885ALDH1A1 1619/4885NPC1 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.